Neurology

ACTRIMS-ECTRIMS 2020 HIGHLIGHTS – Special session on COVID-19

September 28, 2020  

September 13 Edition
September 12 Edition
September 11 Edition

ACTRIMS/ECTRIMS 2020 concluded on September 26th with a special session on COVID-19. Presentations and posters attempted to clarify risk factors for COVID-19 in MS patients, and to address the question of whether disease-modifying therapies (DMT) – most specifically anti-CD20 therapies – affect the risk of acquiring SARS-CoV-2 infection or clinical outcomes of COVID-19. Data were provided by large multinational patient registries and individual MS centres.

Read More

MS curiosities in a curious time

August 20, 2020  

The following are some of the novelties, oddities and curiosities recently published in the multiple sclerosis literature.

HSCT and COVID-19: There is a new report of four MS patients who were diagnosed with COVID-19 in the 6-31 months after receiving autologous hematopoietic stem cell transplant (Gazca et al. Hematology 2020;25:320). Subjects (3F, 1M) were aged 39-54 years. Three contracted COVID-19 from a family member. Only 1 of 4 patients was hospitalized but did not require an ICU stay. No neurological complications of COVID-19 infection were reported. Read More

TOPICS: